uploads/2019/05/Graph-3-9-1.png

Comparing TEVA’s and ENDP’s Earnings Growth Trends in 2019

By

Updated

EPS and EBITDA guidance

In its first-quarter earnings investor presentation, Teva Pharmaceutical (TEVA) reiterated its non-GAAP (generally accepted accounting principles) EPS guidance of $2.20–$2.50 and its EBITDA guidance of $4.4 billion–$4.8 billion for 2019.

In its first-quarter earnings investor presentation, Endo International (ENDP) reiterated its adjusted EBITDA guidance of $1.24 billion–$1.34 billion and its adjusted diluted EPS guidance of $2.00–$2.25 for 2019.

Article continues below advertisement

EPS estimates

Analysts expect Teva Pharmaceutical’s non-GAAP EPS to see YoY (year-over-year) changes of -18.53% to $2.38 in 2019, 8.41% to $2.58 in 2020, and 9.75% to $2.83 in 2021. On the other hand, analysts expect Endo International’s non-GAAP EPS to see YoY changes of -24.69% to $2.18 in 2019, 10.63% to $2.41 in 2020, and -0.57% to $2.39 in 2021.

Analysts expect Teva Pharmaceutical’s non-GAAP EPS to see YoY changes of -26.34% to $0.57 in the second quarter, -13.38% to $0.59 in the third quarter, and 14.01% to $0.60 in the fourth quarter of 2019. Analysts expect Endo International’s non-GAAP EPS to see YoY falls of -37.96% to $0.47 in the second quarter, -22.97% to $0.55 in the third quarter, and -14.56% to $0.64 in the fourth quarter.

EBITDA estimates

Analysts expect Teva Pharmaceutical’s non-GAAP EBITDA to see YoY changes of -12.88% to $4.63 billion in 2019, 4.75% to $4.85 billion in 2020, and 6.74% to $5.18 billion in 2021. On the other hand, analysts expect Endo International’s non-GAAP EBITDA to see YoY changes of -5.29% to $1.28 billion in 2019, 3.11% to $1.32 billion in 2020, and -2.01% to $1.30 billion in 2021.

Analysts expect Teva Pharmaceutical’s non-GAAP EBITDA to see YoY changes of -19.96% to $1.13 billion in the second quarter, -8.10% to $1.15 billion in the third quarter, and 6.67% to $1.16 billion in the fourth quarter. Analysts expect Endo International’s non-GAAP EBITDA to see YoY falls of -14.82% to $298.86 million in the second quarter, -2.88% to $318.90 million in the third quarter, and -0.90% to $341.08 million in the fourth quarter.

Advertisement

More From Market Realist